DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for progressive bulbar palsy — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProgressive bulbar palsy maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for progressive bulbar palsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
methyl-CpG binding protein 2 (MECP2) — MECP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6OGK · 1.65 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
Progressive bulbar palsy is a degenerative disorder of the lower cranial nerve motor nuclei in the medulla, causing gradual paralysis and atrophy of the muscles of the lips, tongue, pharynx, larynx and jaws, leading to difficulties with speech, swallowing, phonation and mastication. A 2025 case report describes a patient with tongue hypertrophy and twitching, dysphagia, dysarthria and excessive secretions, noting that the condition is a terminal illness and that clinicians should recognise the signs to refer patients for neurologic evaluation and symptomatic treatment. A 1932 review states the disease usually begins in the fifth or sixth decade, rarely before age 30, and that its cause was as obscure then as when first described in 1859.
In a subset of childhood forms, genetic causes have been identified. A 2014 review reports that Brown-Vialetto-Van Laere and Fazio-Londe syndromes are now genetically defined, with mutations in the SLC52A2 and SLC52A3 genes, which encode riboflavin transporters, found in about a third of Brown-Vialetto-Van Laere patients. The same review states that riboflavin supplementation can lead to significant clinical improvement if started early in the disease process. However, this applies only to these specific genetic childhood syndromes, not to the adult-onset progressive bulbar palsy described in the older literature.
A 2019 case report warns that Neuro-Behçet’s disease can masquerade as progressive bulbar palsy without the classical peripheral manifestations, and recommends using the International Criteria for Behçet’s Disease for prompt diagnosis and treatment to improve outcome. A 1998 review of progressive supranuclear palsy, a different disorder, is included in the abstracts but does not address progressive bulbar palsy. No drug treatment for adult-onset progressive bulbar palsy is described in any of these abstracts; the only intervention mentioned is riboflavin for a specific genetic childhood form. What is still missing are any controlled trials of drug therapies for adult progressive bulbar palsy, a clear understanding of its cause in most patients, and reliable biomarkers to stratify patients for potential future treatments.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 2014 · 17 citations
Recent advances in bulbar syndromes
AbstractPURPOSE OF REVIEW: With advances in next-generation gene sequencing, progress in deep phenotyping and a greater understanding of the pathogenesis of motor neuron disease, our knowledge of the progressive bulbar syndromes has significantly increased in recent years. This group of heterogeneous conditions, in which the primary disorder is focused around degeneration of the lower cranial nerves, can occur in children or adults and form a spectrum of severity, based around the common feature of bulbar dysfunction. Early genetic diagnosis may allow treatment in some bulbar syndromes. RECENT FINDINGS: Brown-Vialetto-Van Laere and Fazio-Londe syndromes are the most recent childhood forms of progressive bulbar palsy to be genetically defined. The clinical phenotype of this group of childhood disorders was first reported over 120 years ago. Recently, it was demonstrated that in a third of these patients Brown-Vialetto-Van Laere is caused by mutations in the SLC52A2 and SLC52A3 genes, both of which encode riboflavin transporters. Importantly, supplementation of riboflavin can lead to significant clinical improvement if started early in the disease process. SUMMARY: Here, we outline the clinical features, management and an update on the disease mechanisms and genetic causes of the progressive bulbar syndromes.
Archives of Neurology And Psychiatry · 1932 · 11 citations
FAMILIAL PROGRESSIVE BULBAR PARALYSIS
AbstractProgressive bulbar paralysis 1 is an uncommon disease occurring usually in the fifth and sixth decades of life, rarely before the age of 30. It begins insidiously and progresses slowly. The muscles of the lips, tongue, pharynx, larynx and jaws, at first only weakened, later become paralyzed and atrophied, which produces difficulties of speech, deglutition, phonation and mastication. The disease process is a degenerative one causing gradual destruction and finally complete atrophy of the nerve cells forming the most important components of the motor portion of the lower cranial nerves. Although much has been learned about the etiologic factors involved in the acute forms of bulbar paralysis, 2 anterior poliomyelitis and associated diseases, the cause of true progressive bulbar palsy is just as obscure today as when the condition was first recognized by Dumenil 3 in 1859. The gamut of possible factors has been run in an effort to determine
AbstractOBJECTIVE- To review clinical and basic research on progressive supranuclear palsy. METHODS- MEDLINE literature review search from 1966 to 1997. CONCLUSIONS- Significant progress has occurred since Steele, Richardson, and Olzewski first described this disorder as a specific clinicopathologic entity 33 years ago. Clinical features, laboratory testing, and therapeutic strategies are discussed. In addition, hypothesized pathogenetic mechanisms that may help in the search for appropriate biologic therapies are considered.
Developmental Medicine & Child Neurology · 1969 · 7 citations
Progressive Bulbar Palsy
AbstractSUMMARY Progressive bulbar palsy is very rare in childhood. A probable case diagnosed in Greece is presented. After a short review of the literature the clinical and laboratory findings are described. The main clinical features were progressive affection of the bulbar nuclei over one year without involvement of the long tracts. The laboratory findings practically excluded conditions with a similar clinical picture. No autopsy was performed, so the diagnosis remains unproved.
Journal of Pharmacy And Bioallied Sciences · 2025 · 1 citations · open access
Progressive Bulbar Palsy (PBP) or Bulbar Onset MND: “A Case Report”
AbstractA patient with enhancing bulbar palsy, a type of efferent neuron disease that causes hypertrophy and twitching of the tongue's musculature, dysphagia, dysarthria, and an excessive buildup of secretions, is described. Enhancing bulbar palsy is a degenerative disorder of the efferent nuclei in the medulla. The patient may consult a dentist at first. Clinicians must possess knowledge regarding the telltale signs and symptoms of this terminal illness to promptly refer patients for neurologic evaluation and initiate appropriate symptomatic treatments.
Consecutive Lacunar Strokes Mimicking Brainstem Symptoms in a Patient With Pseudobulbar Palsy
AbstractBACKGROUND: The pseudobulbar palsy affects both corticobulbar tracts leading to symptoms of the caudal brain nerves. These bulbar symptoms often may be misinterpreted and lead to a false localization of the ischemic lesion. Here we report on a patient with an acute small lacunar ischemic lesion who presented clinically with severe affection because of an identical old contralateral lesion. CASE REPORT: The patient presented with sudden onset of dysphagia, anarthria, and glossplegia. The clinical examination was suspicious of a brainstem lesion, however, stroke magnetic resonance imaging revealed a small ischemic lacuna within the right internal capsule. However, because of an old ischemic lesion within the left internal capsule, both corticobulbar tracts were involved and this pseudobulbar palsy was mimicking bulbar brainstem symptoms. DISCUSSION: Patients who suffer from a pseudobulbar palsy usually have—compared with the rather small lesions within the central nervous system—clinically dramatic presentations and due to bulbar symptoms severe medical secondary complications and social-economic consequences to deal with.
AbstractProgressive supranucleair palsy (PSP) is a serious neurologic disease which is seldom diagnosed due to its complexity. In 1996 international diagnostic criteria were developed by a group of experts, the diagnosis remains complicated. We describe three cases, which were followed in the period 2001-2008. In these case reports we elaborate on the therapeutic use of rivastigmine. During off-label rivastigmine use, patients showed minimal further cognitive decline, specifically with respect to frontal defects. However, larger studies and trials are necessary to explore the effects of rivastigmine in patients with PSP.
Neuro-Behçet’s masquerading as progressive bulbar palsy: a case report and literature review
AbstractIn patients with progressive bulbar palsy without an obvious cause, there should be a high index of suspicion for the potential diagnosis of Neuro-Behçet's Disease, even in the absence of the acute classical peripheral manifestations of Bechet's Disease, with emphasis in prompt diagnosis using 'The International Criteria for Behçet's Disease' and rapid, effective treatment in order to improve outcome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
